Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 156
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 143
Ivermectin for preventing and treating COVID-19
Maria Popp, Miriam Stegemann, Maria‐Inti Metzendorf, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 89
Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis
Stephanie Weibel, Maria Popp, Stefanie Reis, et al.
Research Synthesis Methods (2022) Vol. 14, Iss. 3, pp. 357-369
Open Access | Times Cited: 54
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Andrew Hill, Manya Mirchandani, Victoria Pilkington
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 2
Open Access | Times Cited: 51
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Anant Mohan, Pawan Tiwari, Tejas Menon Suri, et al.
Journal of Infection and Chemotherapy (2021) Vol. 27, Iss. 12, pp. 1743-1749
Open Access | Times Cited: 53
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Zheng Yao Low, Ashley Jia Wen Yip, Sunil K. Lal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 2, pp. 166294-166294
Open Access | Times Cited: 42
Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review
Dena Zeraatkar, Tyler Pitre, Gareth Leung, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000309-e000309
Open Access | Times Cited: 33
Retracted randomized controlled trials were cited and not corrected in systematic reviews and clinical practice guidelines
Yuki Kataoka, Masahiro Banno, Yasushi Tsujimoto, et al.
Journal of Clinical Epidemiology (2022) Vol. 150, pp. 90-97
Open Access | Times Cited: 31
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 7
Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients
Sabine Hazan, Sonya Davé, Anoja W. Gunaratne, et al.
Future Microbiology (2022) Vol. 17, Iss. 5, pp. 339-350
Open Access | Times Cited: 26
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
Mohsen Nabi‐Afjadi, Fatemeh Mohebi, Hamidreza Zalpoor, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 1, pp. 21-35
Open Access | Times Cited: 15
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
Mario Cruciani, Ilaria Pati, Francesca Masiello, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1645-1645
Open Access | Times Cited: 32
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Arman Shafiee, Mohammad Mobin Teymouri Athar, Omid Kohandel Gargari, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results
Ariel Izcovich, Sasha Peiris, Martín Ragusa, et al.
Journal of Clinical Epidemiology (2021) Vol. 144, pp. 43-55
Open Access | Times Cited: 26
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Alessandro D. Santin, David Scheim, Peter A. McCullough, et al.
New Microbes and New Infections (2021) Vol. 43, pp. 100924-100924
Open Access | Times Cited: 25
RETRACTED: Samaha et al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021, 13, 989
Ali Samaha, Hussein Mouawia, Mirna Fawaz, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2154-2154
Open Access | Times Cited: 19
Biased, wrong and counterfeited evidences published during the COVID-19 pandemic, a systematic review of retracted COVID-19 papers
Angelo Capodici, Aurelia Salussolia, Francesco Sanmarchi, et al.
Quality & Quantity (2022) Vol. 57, Iss. 5, pp. 4881-4913
Open Access | Times Cited: 13
An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients
Smruti Karale, Vikas Bansal, Janaki Makadia, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 15
Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis
Sanjana Nagraj, Dimitrios Varrias, Gabriel Hernández Romero, et al.
Stroke (2022) Vol. 53, Iss. 11, pp. 3410-3418
Open Access | Times Cited: 11
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
Carmen de la Rocha, Marco A. Cid-López, Blanca I. Venegas-López, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Alireza Mirahmadizadeh, Ali Semati, Alireza Heiran, et al.
Respirology (2022) Vol. 27, Iss. 9, pp. 758-766
Open Access | Times Cited: 7
Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19
Hoda Awad, Basmala Hassan, Sara Dweek, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1068-1068
Open Access | Times Cited: 6
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection
Zsuzsanna Ragó, Barbara Tóth, Ágnes Szalenkó-Tőkés, et al.
GeroScience (2023) Vol. 45, Iss. 4, pp. 2179-2193
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top